NASDAQ:AIMT - Aimmune Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aimmune Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.42 -0.13 (-0.89 %) (As of 04/1/2020 05:06 AM ET) Add Compare Today's Range$14.02Now: $14.42▼$15.3050-Day Range$11.48MA: $20.51▼$29.5052-Week Range$10.09Now: $14.42▼$37.00Volume1.45 million shsAverage Volume2.00 million shsMarket Capitalization$903.70 millionP/E RatioN/ADividend YieldN/ABeta0.38 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AIMT Previous Symbol CUSIPN/A CIK1631650 Webhttp://www.aimmune.com/ Phone650-614-5220Debt Debt-to-Equity Ratio0.50 Current Ratio3.14 Quick Ratio3.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.66 per share Price / Book8.69Profitability EPS (Most Recent Fiscal Year)($3.97) Net Income$-248,500,000.00 Net MarginsN/A Return on Equity-138.44% Return on Assets-90.72%Miscellaneous Employees228 Outstanding Shares62,670,000Market Cap$903.70 million Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive AIMT News and Ratings via Email Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AIMT Rates by TradingView Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions How has Aimmune Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Aimmune Therapeutics' stock was trading at $17.57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AIMT stock has decreased by 17.9% and is now trading at $14.42. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aimmune Therapeutics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aimmune Therapeutics. When is Aimmune Therapeutics' next earnings date? Aimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Aimmune Therapeutics. How were Aimmune Therapeutics' earnings last quarter? Aimmune Therapeutics Inc (NASDAQ:AIMT) announced its quarterly earnings data on Thursday, February, 27th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($1.06). During the same quarter in the prior year, the firm posted ($0.95) EPS. View Aimmune Therapeutics' earnings history. What price target have analysts set for AIMT? 11 Wall Street analysts have issued 12 month target prices for Aimmune Therapeutics' shares. Their forecasts range from $27.00 to $66.00. On average, they expect Aimmune Therapeutics' stock price to reach $43.45 in the next year. This suggests a possible upside of 201.3% from the stock's current price. View analysts' price targets for Aimmune Therapeutics. What are Wall Street analysts saying about Aimmune Therapeutics stock? Here are some recent quotes from research analysts about Aimmune Therapeutics stock: 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (2/5/2020) 2. Stifel Nicolaus analysts commented, "We continue to expect the focus of the Adcom to be on safety – risk of anaphylaxis and use of epinephrine – which is not new" news and we think also around the long-term use/safety of AR101 in patients (i.e. EoE). We think this should provide some relief for shares today as the investors’ worst case" scenario in terms of the panel may be off the table as the agency struck a relatively positive tone in the docs, in our view. With the stock continuing to move up ahead of the Adcom, we think the risk/reward at these levels is less favorable once Palforzia is approved given the commercial/logistical challenges we feel lay ahead, which is core to our thesis, and the Adcom isn’t completely devoid of risk." (9/11/2019) Has Aimmune Therapeutics been receiving favorable news coverage? Media stories about AIMT stock have trended very negative on Wednesday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aimmune Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutAimmune Therapeutics. Are investors shorting Aimmune Therapeutics? Aimmune Therapeutics saw a decline in short interest in the month of March. As of March 13th, there was short interest totaling 14,208,700 shares, a decline of 6.2% from the February 27th total of 15,150,000 shares. Based on an average daily trading volume, of 1,295,300 shares, the short-interest ratio is currently 11.0 days. Approximately 32.6% of the shares of the company are sold short. View Aimmune Therapeutics' Current Options Chain. Who are some of Aimmune Therapeutics' key competitors? Some companies that are related to Aimmune Therapeutics include Evotec (EVTCY), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Blueprint Medicines (BPMC), Nektar Therapeutics (NKTR), FibroGen (FGEN), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB), Ultragenyx Pharmaceutical (RARE) and PPD (SDGR). What other stocks do shareholders of Aimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), AbbVie (ABBV), CA (CA), Amarin (AMRN), Brainstorm Cell Therapeutics (BCLI), Roku (ROKU) and BlackRock (BLK). Who are Aimmune Therapeutics' key executives? Aimmune Therapeutics' management team includes the following people: Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)Dr. Stephen George Dilly, Special Advisor (Age 59)Dr. Daniel C. Adelman, Chief Medical Officer (Age 62) When did Aimmune Therapeutics IPO? (AIMT) raised $124 million in an IPO on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO. What is Aimmune Therapeutics' stock symbol? Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT." How do I buy shares of Aimmune Therapeutics? Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aimmune Therapeutics' stock price today? One share of AIMT stock can currently be purchased for approximately $14.42. How big of a company is Aimmune Therapeutics? Aimmune Therapeutics has a market capitalization of $903.70 million. The biotechnology company earns $-248,500,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe. View additional information about Aimmune Therapeutics. What is Aimmune Therapeutics' official website? The official website for Aimmune Therapeutics is http://www.aimmune.com/. How can I contact Aimmune Therapeutics? Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected] MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 452 (Vote Outperform)Underperform Votes: 306 (Vote Underperform)Total Votes: 758MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/1/2020 by MarketBeat.com StaffFeatured Article: What economic reports are most valuable to investors?
